New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA

Circulation

Volumn 92, Issue 10, 1995, Pages 3032-3040

  Benedict, Claude R ^a,c   Refino, Canio J ^b   Keyt, Bruce A ^b   Pakala, Rajbabu ^a   Paoni, Nicholas F ^b   Thomas, G Rodger ^b   Bennett, William F ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b GENENTECH INC   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

blood flow; occlusion; plasminogen activators; thrombolysis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; CHROMOGENIC SUBSTRATE; FIBRIN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UROKINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTERY BLOOD FLOW; ARTICLE; BLEEDING; CAROTID ARTERY THROMBOSIS; CHO CELL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENCY; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECANALIZATION; THROMBOCYTE AGGREGATION;

EID: 0028821715     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.92.10.3032     Document Type: Article

References (46)

1. Collen D, Topol EJ, Tiefenbrunn AJ, Gold HK, Weisfeldt ML, Sobel BE, Leinbach RC, Brinker JA, Ludbrook PA, Yasuda I, Bulkley BH, Robinson AF, Hutter AM Jr, Bell WR, Spadaro JJ Jr, Khaw BA, Grossbard EB. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation. 1984;70:1012-1017.
2. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL, Braunwald E. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase 1: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation. 1987;76: 142-154.
3. Anderson JL, Rothbard RL, Hackworthy RA, Sorensen SG, Fitzpatrick PG, Dahl CF, Hagan AD, Browne KF, Symkoviak GP, Menlove RL, Barry WH, Eckerson HW, Marder VJ. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. J Am Coll Cardiol. 1988;2:1153-1163.
4. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
5. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wave front phenomenon of ischemic cell death, I: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56: 786-794.
6. Bush LR, Buja LM, Samowitz Q, Rude RE, Wathen M, Tilton GD, Willerson JT. Recovery of left ventricular segmental function after long-term reperfusion following temporary coronary occlusion in conscious dogs. Circ Res. 1983;53:248-263.
7. Bergmann SR, Lerch RA, Fox KA, Ludhrook PA, Welch MJ, Ter-Pogossian MM, Sobel BE. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med. 1982;73:573-581.
8. GISSI Study Group. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397-401.
9. Serruys PW, Simoons ML, Suryapranata H, Vermeer F, Wijns W, van den Brand M, Bar F, Zwaan C, Krauss XH, Remme WJ, Res J, Verbeugt FWA, van Domburg R, Lubsen J, Hugenholtz PG. Preservation of global and regional left ventricular function after early thrombolysis in acute myocardial infarction. J Am Coll Cardiol. 1986;7:729-742.
10. Van de Werf F, Arnold AER. Intravenous tissue plasminogen activator and size of infarct, left ventricular function and survival in acute myocardial infarction. Br Med J. 1988;297:1374-1379.
11. The ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). N Engl J Med. 1986;314:1465-1471.
12. Ikram S, Lewis S, Bucknall C, Sram I, Thomas N, Vincent R, Chamberlain D. Treatment of acute myocardial infarction with anisoylated plasminogen streptokinase activator complex. Br Med J. 1986;293:786-789.
13. The GUSTO Angiographie Investigators. The effect of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
14. Smalling RW, Schumacher R, Morris D, Karder K, Fuentes F, Valentine RP, Battey LL Jr, Merhige M, Pitts DE, Liederman HA, Nishikawa A, Adyanthaya A, Hopkins A. Improved infarct-related arterial patency after high dose, weight-adjusted, rapid infusion of tissue-type plasminogen activator in myocardial infarction: results of a multicenter randomized trial of two dosage regimens. J Am Coll Cardiol. 1990;15:915-921.
15. Wu A, van de Werf F, Stassen T, Mattsson C, Pohl G, Collen D. Pharmacokinetics and coronary thrombolytic properties of two human tissue-type plasminogen activator variants lacking the finger-like, growth factor-like, and first kringle domains (amino acids 6-173) in a canine model. J Cardiovasc Pharmacol. 1990;16: 197-203.
16. Keyt BA, Paoni NF, Refino CJ, Berleau L, Nguyen H, Chow A, Lai J, Pena L, Pater C, Ogez J, Etcheverry T, Botstein D, Bennett WF. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA. 1994;91:3670-3674.
17. Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Pena L, Brady K, Wurm FM, Ogez J, Bennett WF. A slow clearing, fibrin-specific, PAI-1 resistant variant of tPA (T103N, KHRR 296-299 AAAA). Thromb Haemost. 1993;70:307-312.
18. Benedict CR, Mathew B, Rex KA, Cartwright J Jr, Sordahl LA. Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ Res. 1986;73:58-67.
19. Benedict CR, Ryan J, Wolitzky B, Gerlach M, Stern D. Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model. J Clin Invest. 1991;88: 1760-1765.
20. Benedict CR, Ryan J, Todd J, Kuwabara K, Tijburg P, Cartwright J Jr, Stern D. Active site-blocked factor Xa prevents intravascular thrombus formation in the coronary vasculature in parallel with inhibition of extravascular coagulation in a canine thrombosis model. Blood. 1993;81:2059-2066.
21. Neuhaus K-L, Feuerer WJ, Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombolysis with a modified dose regimen of tissue-type plasminogen activator. J Am Coll Cardiol. 1989;14:1566-1569.
22. 2 modulate the response to tissue-type plasminogen activation in vivo. Circ Res. 1989;65:83-94.
23. Eisenberg PR. Pro-coagulant effects of fibrinolytic agents. In: Sobel BE, Collen D, eds. Coronary Thrombolysis in Perspective. New York, NY: Marcel Dekker Inc; 1993:75-99.
24. Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss JA. D-Phe-Pro-Arg-chloromethylketone: its potential use in inhibiting the formation of in vivo artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemost. 1986;56:160-164.
25. Clauss A. Gerinnungsphysiologische schnellmcthode zur bestimmung des fibrinogens. Acta Haematol. 1957;17:237-240.
26. Soria J, Soria C, Samama MM. A plasminogen assay using a chromogenic synthetic substrate: results from clinical work and studies ot thrombolysis. In: Davidson JF, Samama MM, Desnoyers PC, eds. Chemical Fibrinolysis and Thrombolysis. New York, NY: Raven Press Publishers; 1978;3:337-346.
27. Berleau L, Nguyen H, Modi N, Bennett W, Keyt BA. Pharmacokinetics and pharmacodynamics of TPA variants in rabbits. Thromb Haemost. 1993:69:1070. Abstract.
28. Higgins D, Bennett W. Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis. Annu Rev Pharmacol Toxicol. 1990;30:91-121.
29. Lijnen HR, Collen D. Strategies for the improvement of thrombolytic agents. Thromb Haemost. 1991;66:88-110.
30. Refino CJ, Keyt BA, Paoni NF, Badillo JM, Pater CS, Van Peborgh J, Pena L, Berleau LT, Nguyen VH, Bennett WF. A variant of tissue plasminogen activator (T103N, N117Q, KHRR 296-299 AAAA) with a decreased plasma clearance rate is substantially more potent than Activase rt-PA in rabbit thrombolysis model. Thromb Haemost. 1993;69:841. Abstract.
31. Hofmann KJ, Mayer EJ, Schultz LD, Socher SH, Reily CF. Purification and characterization of recombinant rabbit plasminogen activator inhibitor-1 expressed in Sacchammyces cerevisiae. Fibrinolysis. 1992;6:263-272.
32. Refino CJ, Paoni NF, Keyt BA, Pater CS, Badillo JM, Wurm FM, Ogez J, Bennett WF. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen. Thromb Haemost. 1993;70: 313-319.
33. Thomas GR, Thibodeaux H, Errett CJ, Badillo JM, Keyt BA, Refino CJ, Zivin JA, Bennett WF. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolie stroke and peripheral bleeding. Stroke. 1994;25:2072-2079.
34. Collen D, Stassen J-M, Yasuda T, Refino CJ, Paoni N, Keyt BA, Roskams T, Guerrero JL, Lijnen HR, Gold HK, Bennett WF. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog, Thromb Haemost. 1994;72:98-104.
35. Refino CJ, Badillo JM, Paoni NF, Keyt BA, Nguyen HV, Bennett WF. Increasing the fibrin specificity of t-PA enhances its activity towards platelet rich clots. Fibrinolysis. 1994;8(suppl 1):313.
36. Sobel BE, Nachowiak DA, Fry ETA, Bergman SR, Torr SR. Paradoxical attenuation of fibrinolysis attributable to 'plasminogen steal' and its implications for coronary thrombolysis. Coron Artery Dis. 1990;1:111-119.
37. Thomas GR, Thibodeaux H, Bennett WF, Refino CF, Badillo JM, Errett CJ, Zivin JA. Optimized thrombolysis of cerebral clots with tissue-type plasminogen activator in a rabbit model of embolic stroke. J Pharmcol Exp Ther. 1993;264:67-73.
38. The TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial. N Engl J Med. 1985;312:932-936.
39. Verstraete M, Bernard R, Bory M, Brower RW, Collen D, de Bono DP, Erbel R, Huhmann W, Lennane RJ, Lubsen J, Mathey D, Meyer J, Michels HR, Rutsch W, Schartl MM, Schmidt W, Uebis R, von Essen R. Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction. Lancet. 1985;1:842-847.
40. White HD, Rivers JT, Maslowski AH, Ormiston JA, Takayama M, Hart HH, Sharpe DN, Whitlock RML, Norris RM. Effect of intravenous streptokinase as compared with that of tissue plasminogen activator on left ventricular function after first myocardial infarction. N Engl J Med. 1989;320:817-821.
41. Magnani B for the PAIMS investigators. Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (tPA) with intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol. 1989;13:19-26.
42. Arnold AER, Brower RW, Collen D, van Es G-A, Lubsen J, Serruys PW, Simoons ML, Verstraete M, for the European Co-operative Study Group for rt-PA. Increased serum levels of fibrinogen degradation products due to treatment with recombinant tissue-type plasminogen activator for acute myocardial infarction are related to bleeding complications, but not to coronary patency. J Am Coll Cardiol. 1989;14:581-588.
43. Rao AK, Pratt C, Berke A, Jaffe A, Ochene I, Schreiber TL, Bell RW, Knatterud G, Robertson TL, Terrin ML, for the TIMI investigators. Thrombolysis in Myocardial Infarction (TIMI) trial - phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1-11.
44. Fennerty AG, Levine MN, Hirsh J. Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. Chest. 1989;95:885-895.
45. Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D, and the TAMI study group. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator: correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation. 1989;80: 1222-1230.
46. Marder VJ, Sherry S. Thrombolytic therapy: current status. N Engl J Med. 1988;380:1512-1520.